Drug Substance Technologies, Process Development, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA.
Biotechnol J. 2020 Jan;15(1):e1900247. doi: 10.1002/biot.201900247. Epub 2019 Nov 27.
During biomanufacturing cell lines development, the generation and screening for single-cell derived subclones using methods that enable assurance of clonal derivation can be resource- and time-intensive. High-throughput miniaturization, automation, and analytic strategies are often employed to reduce such bottlenecks. The Beacon platform from Berkeley Lights offers a strategy to eliminate these limitations through culturing, manipulating, and characterizing cells on custom nanofluidic chips via software-controlled operations. However, explicit demonstration of this technology to provide high assurance of a single cell progenitor has not been reported. Here, a methodology that utilizes the Beacon instrument to ensure high levels of clonality is described. It is demonstrated that the Beacon platform can efficiently generate production cell lines with a superior clonality data package, detailed tracking, and minimal resources. A stringent in-process quality control strategy is established to enable rapid verification of clonal origin, and the workflow is validated using representative Chinese hamster ovary-derived cell lines stably expressing either green or red fluorescence protein. Under these conditions, a >99% assurance of clonal origin is achieved, which is comparable to existing imaging-coupled fluorescence-activated cell sorting seeding methods.
在生物制造细胞系开发过程中,使用能够保证克隆起源的方法对单细胞衍生的亚克隆进行生成和筛选可能会耗费大量的资源和时间。通常采用高通量微型化、自动化和分析策略来减少这些瓶颈。Berkeley Lights 的 Beacon 平台提供了一种策略,通过软件控制操作,在定制的纳流控芯片上培养、操作和表征细胞,从而消除这些限制。然而,尚未有报道明确证明该技术可提供单细胞前体的高度保证。在这里,描述了一种利用 Beacon 仪器确保高克隆性的方法。结果表明,Beacon 平台可以有效地生成具有优异克隆性数据包、详细跟踪和最小资源的生产细胞系。建立了严格的过程质量控制策略,以实现快速验证克隆起源,并且使用代表性的稳定表达绿色或红色荧光蛋白的中国仓鼠卵巢衍生细胞系验证了工作流程。在这些条件下,可实现 >99%的克隆起源保证,与现有的成像偶联荧光激活细胞分选播种方法相当。